Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides

International Journal of Medical Microbiology

Volumn 299, Issue 5, 2009, Pages 313-322

  Sass, Peter ^a   Bierbaum, Gabriele ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Antibiotics; graRS; Mersacidin; Staphylococcus aureus SG511

Indexed keywords

BACITRACIN; CYTOPLASM PROTEIN; INDOLICIDIN; LANTIBIOTIC; MERSACIDIN; NISIN; NUCLEOTIDE; PEP5; PROTEIN HISTIDINE KINASE; PROTEIN HISTIDINE KINASE GRAS; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CELL SURFACE; CYTOPLASM; DLTB GENE; GENE; GENE CONTROL; GENETIC TRANSCRIPTION; MICROBIAL IDENTIFICATION; MINIMUM INHIBITORY CONCENTRATION; MPRF GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STOP CODON; VRAFG GENE;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIOCINS; CODON, NONSENSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC COMPLEMENTATION TEST; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; POINT MUTATION; PROTEIN KINASES; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS AUREUS;

EID: 67349119801     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2008.10.005     Document Type: Article

References (44)

1. Barrett M.S., Wenzel R.P., and Jones R.N. In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates. Diagn. Microbiol. Infect. Dis. 15 (1992) 641-644
2. Bierbaum G., and Sahl H.G. Autolytic system of Staphylococcus simulans 22: influence of cationic peptides on activity of N-acetylmuramoyl-l-alanine amidase. J. Bacteriol. 169 (1987) 5452-5458
3. Brötz H., Bierbaum G., Reynolds P.E., and Sahl H.G. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 246 (1997) 193-199
4. Brötz H., Bierbaum G., Leopold K., Reynolds P.E., and Sahl H.G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42 (1998) 154-160
5. Chatterjee S., Chatterjee D.K., Jani R.H., Blumbach J., Ganguli B.N., Klesel N., Limbert M., and Seibert G. Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. (Tokyo) 45 (1992) 839-845
6. de Jonge B.L., Sidow T., Chang Y.S., Labischinski H., Berger-Bächi B., Gage D.A., and Tomasz A. Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus. J. Bacteriol. 175 (1993) 2779-2782
7. Enright M.C., Day N.P., Davies C.E., Peacock S.J., and Spratt B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38 (2000) 1008-1015
8. Garrard W., and Lascelles J. Regulation of Staphylococcus aureus lactate dehydrogenase. J. Bacteriol. 95 (1968) 152-156
9. Goerke C., Koller J., and Wolz C. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (2006) 171-177
10. Gordon R.J., and Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46 Suppl. 5 (2008) S350-S359
11. Herbert S., Bera A., Nerz C., Kraus D., Peschel A., Goerke C., Meehl M., Cheung A., and Götz F. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS. Pathog. 3 (2007) e102
12. Holden M.T., Feil E.J., Lindsay J.A., Peacock S.J., Day N.P., Enright M.C., Foster T.J., Moore C.E., Hurst L., Atkin R., Barron A., Bason N., Bentley S.D., Chillingworth C., Chillingworth T., Churcher C., Clark L., Corton C., Cronin A., Doggett J., Dowd L., Feltwell T., Hance Z., Harris B., Hauser H., Holroyd S., Jagels K., James K.D., Lennard N., Line A., Mayes R., Moule S., Mungall K., Ormond D., Quail M.A., Rabbinowitsch E., Rutherford K., Sanders M., Sharp S., Simmonds M., Stevens K., Whitehead S., Barrell B.G., Spratt B.G., and Parkhill J. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl. Acad. Sci. USA 101 (2004) 9786-9791
13. Howden B.P., Stinear T.P., Allen D.L., Johnson P.D., Ward P.B., and Davies J.K. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (2008) 3755-3762 10.1128/AAC.01613-07
14. Hsu S.T., Breukink E., Bierbaum G., Sahl H.G., de Kruijff B., Kaptein R., van Nuland N.A., and Bonvin A.M. NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278 (2003) 13110-13117
15. Jansen A., Türck M., Szekat C., Nagel M., Clever I., and Bierbaum G. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int. J. Med. Microbiol. 297 (2007) 205-215
16. Johnson A.P., Aucken H.M., Cavendish S., Ganner M., Wale M.C., Warner M., Livermore D.M., and Cookson B.D. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J. Antimicrob. Chemother. 48 (2001) 143-144
17. Jordan S., Hutchings M.I., and Mascher T. Cell envelope stress response in Gram-positive bacteria. FEMS Microbiol. Rev. 32 (2008) 107-146
18. Kraus D., Herbert S., Kristian S.A., Khosravi A., Nizet V., Götz F., and Peschel A. The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol. 8 (2008) 85
19. Kreiswirth B.N., Löfdahl S., Betley M.J., O'Reilly M., Schlievert P.M., Bergdoll M.S., and Novick R.P. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305 (1983) 709-712
20. Lampilas, M., Vogel, S., 1999. Moenomycin A derivatives, their preparation, and use as antibacterial products. Patent number EP1069130.
21. Li M., Cha D.J., Lai Y., Villaruz A.E., Sturdevant D.E., and Otto M. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol. 66 (2007) 1136-1147
22. Li M., Lai Y., Villaruz A.E., Cha D.J., Sturdevant D.E., and Otto M. Gram-positive three-component antimicrobial peptide-sensing system. Proc. Natl. Acad. Sci. USA 104 (2007) 9469-9474
23. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 339 (1998) 520-532
24. Maidhof H., Johannsen L., Labischinski H., and Giesbrecht P. Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent. J. Bacteriol. 171 (1989) 2252-2257
25. Meehl M., Herbert S., Götz F., and Cheung A. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51 (2007) 2679-2689
26. Naumann, D., Labischinski, H., 1990. Process and device for rapid testing of the effect of agents on micro-organisms. Patent number EP1069130.
27. Neoh H.M., Cui L., Yuzawa H., Takeuchi F., Matsuo M., and Hiramatsu K. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52 (2008) 45-53
28. Pag U., Oedenkoven M., Sass V., Shai Y., Shamova O., Antcheva N., Tossi A., and Sahl H.G. Analysis of in vitro activities and modes of action of synthetic antimicrobial peptides derived from an alpha-helical 'sequence template'. J. Antimicrob. Chemother. 61 (2008) 341-352
29. Peschel A., Ottenwalder B., and Götz F. Inducible production and cellular location of the epidermin biosynthetic enzyme EpiB using an improved staphylococcal expression system. FEMS Microbiol. Lett. 137 (1996) 279-284
30. Peschel A., Otto M., Jack R.W., Kalbacher H., Jung G., and Götz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274 (1999) 8405-8410
31. Peschel A., Vuong C., Otto M., and Götz F. The d-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob. Agents Chemother. 44 (2000) 2845-2847
32. Peschel A., Jack R.W., Otto M., Collins L.V., Staubitz P., Nicholson G., Kalbacher H., Nieuwenhuizen W.F., Jung G., Tarkowski A., van Kessel K.P., and van Strijp J.A. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med 193 (2001) 1067-1076
33. Pöhn H.-P. Zur Frage der Einheitlichkeit des Staphylokokken-Stammes "SG 511". Zentralbl. Bakteriol. Abt. Orig. 177 (1959) 432
34. Pulverer G., and Grün L. Studies on the differentiation of the Staphylococcus standard strain "SG 511". Z. Hyg. Infektionskr. 146 (1960) 537-543
35. Ramakrishna, N.V.S., Bhat, R.G., Sreekumar, S.A.W., Vijayakumar, E.K.S., Naker, S., Oak, U., Tanpure, R.G.C., Hopmann, C., Kurz, M., Wink, J., Seibert, G., Le Beller, D., Aszodi, J., 2002. Vancoresmycin, a process for its production and its use as a pharmaceutical. Patent Nr. EP 1129208.
36. Reipert A., Ehlert K., Kast T., and Bierbaum G. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob. Agents Chemother. 47 (2003) 568-576
37. Robinson D.A., and Enright M.C. Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47 (2003) 3926-3934
38. Sahl H.G., and Brandis H. Efflux of low-Mr substances from the cytoplasm of sensitive cells caused by the staphylococcin-like agent Pep5. FEMS Microbiol. Lett. 16 (1983) 75-79
39. Sahl H.G., Hahn C., and Brandis H. Interaction of the staphylococcin-like peptide Pep 5 with cell walls and isolated cell wall components of Gram-positive bacteria. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 260 (1985) 197-205
40. Saïd-Salim B., Dunman P.M., McAleese F.M., Macapagal D., Murphy E., McNamara P.J., Arvidson S., Foster T.J., Projan S.J., and Kreiswirth B.N. Global regulation of Staphylococcus aureus genes by Rot. J. Bacteriol. 185 (2003) 610-619
41. Sass, P., Jansen, A., Szekat, C., Sass, V., Sahl, H.G., Bierbaum, G., 2008a. The lantibiotic mersacidin is a strong inducer of the cell wall stress response of Staphylococcus aureus. BMC Microbiology 8, 186.
42. Sass V., Pag U., Tossi A., Bierbaum G., and Sahl H.G. Mode of action of human beta-defensin 3 (hBD3) against Staphylococcus aureus and transcriptional analysis of responses to defensin challenge. Int. J. Med. Microbiol. 298 (2008) 613-633 10.1016/j.ijmm.2008.01.011
43. Schenk S., and Laddaga R.A. Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol. Lett. 73 (1992) 133-138
44. Schneider T.R., Karcher J., Pohl E., Lubini P., and Sheldrick G.M. Ab initio structure determination of the lantibiotic mersacidin. Acta Crystallogr. D. Biol. Crystallogr. 56 (2000) 705-713